Seizures associated with clozapine augmentation by other antipsychotics: a pharmacovigilance-pharmacodynamic analysis using VigiBase.

IF 5 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Therapeutic Advances in Psychopharmacology Pub Date : 2026-07-30 eCollection Date: 2026-01-01 DOI:10.1177/20451253261472920
Masakazu Hatano, Hirofumi Hamano, Masaya Kanda, Takenao Koseki, Tsuyoshi Nakai, Rina Horii, Nozomi Yoshihara, Takeo Saito, Kenshi Takechi, Satoru Esumi, Yoshito Zamami, Shigeki Yamada
{"title":"Seizures associated with clozapine augmentation by other antipsychotics: a pharmacovigilance-pharmacodynamic analysis using VigiBase.","authors":"Masakazu Hatano, Hirofumi Hamano, Masaya Kanda, Takenao Koseki, Tsuyoshi Nakai, Rina Horii, Nozomi Yoshihara, Takeo Saito, Kenshi Takechi, Satoru Esumi, Yoshito Zamami, Shigeki Yamada","doi":"10.1177/20451253261472920","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Clozapine is associated with a high risk of central nervous system abnormalities. However, seizure risk related to interactions between clozapine and other antipsychotics remains poorly characterized, and the pharmacological mechanisms underlying these seizures are unclear.</p><p><strong>Objectives: </strong>We aimed to evaluate safety signals for seizures associated with clozapine augmentation by other antipsychotics and analyze the relationship between these signals and neurotransmitter receptor occupancy profiles.</p><p><strong>Design: </strong>A pharmacovigilance-pharmacodynamic analysis using a spontaneous reporting system.</p><p><strong>Methods: </strong>This pharmacovigilance study used VigiBase, an adverse drug reaction database maintained by the World Health Organization. Drug-drug interactions (DDIs) between clozapine and other antipsychotics were assessed using the Ω shrinkage measure model. The association between DDI signals and neurotransmitter receptor occupancy was evaluated using linear regression. Robustness was tested using four frequency statistical models: additive, multiplicative, combination risk ratio, and chi-square statistic models.</p><p><strong>Results: </strong>Of 38,758,077 reports in VigiBase between 1990 and 2024, 230,371 involved clozapine. Among antipsychotics classified under ATC code N05A, DDIs with clozapine were detected for amisulpride, chlorpromazine, haloperidol, lurasidone, olanzapine, penfluridol, risperidone, sulpiride, zotepine, and zuclopenthixol. A significant association between dopamine D<sub>4</sub> receptor occupancy and the point estimates of signal values was observed in the Ω shrinkage measure model (β = 0.295, 95% confidence interval: 0.119-0.471, <i>p</i> = 0.002) and replicated across all frequency statistical models.</p><p><strong>Conclusions: </strong>These findings suggest a potential role of dopamine D<sub>4</sub> receptor occupancy in seizures associated with clozapine augmentation by other antipsychotics. Further large-scale epidemiological studies are needed to validate these findings.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"16 ","pages":"20451253261472920"},"PeriodicalIF":5.0000,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13424776/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20451253261472920","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Clozapine is associated with a high risk of central nervous system abnormalities. However, seizure risk related to interactions between clozapine and other antipsychotics remains poorly characterized, and the pharmacological mechanisms underlying these seizures are unclear.

Objectives: We aimed to evaluate safety signals for seizures associated with clozapine augmentation by other antipsychotics and analyze the relationship between these signals and neurotransmitter receptor occupancy profiles.

Design: A pharmacovigilance-pharmacodynamic analysis using a spontaneous reporting system.

Methods: This pharmacovigilance study used VigiBase, an adverse drug reaction database maintained by the World Health Organization. Drug-drug interactions (DDIs) between clozapine and other antipsychotics were assessed using the Ω shrinkage measure model. The association between DDI signals and neurotransmitter receptor occupancy was evaluated using linear regression. Robustness was tested using four frequency statistical models: additive, multiplicative, combination risk ratio, and chi-square statistic models.

Results: Of 38,758,077 reports in VigiBase between 1990 and 2024, 230,371 involved clozapine. Among antipsychotics classified under ATC code N05A, DDIs with clozapine were detected for amisulpride, chlorpromazine, haloperidol, lurasidone, olanzapine, penfluridol, risperidone, sulpiride, zotepine, and zuclopenthixol. A significant association between dopamine D4 receptor occupancy and the point estimates of signal values was observed in the Ω shrinkage measure model (β = 0.295, 95% confidence interval: 0.119-0.471, p = 0.002) and replicated across all frequency statistical models.

Conclusions: These findings suggest a potential role of dopamine D4 receptor occupancy in seizures associated with clozapine augmentation by other antipsychotics. Further large-scale epidemiological studies are needed to validate these findings.

癫痫发作与其他抗精神病药物增强氯氮平相关:使用VigiBase进行药物警戒-药效学分析
背景:氯氮平与中枢神经系统异常的高风险相关。然而,与氯氮平和其他抗精神病药物相互作用相关的癫痫发作风险仍然不清楚,并且这些癫痫发作的药理学机制尚不清楚。目的:我们旨在评估与其他抗精神病药物氯氮平增强相关的癫痫发作的安全信号,并分析这些信号与神经递质受体占用谱之间的关系。设计:采用自发报告系统进行药物警戒-药效学分析。方法:本药物警戒研究使用VigiBase,一个由世界卫生组织维护的药物不良反应数据库。使用Ω收缩测量模型评估氯氮平与其他抗精神病药物之间的药物相互作用(ddi)。使用线性回归评估DDI信号与神经递质受体占用之间的关系。采用四种频率统计模型进行稳健性检验:加性、乘性、组合风险比和卡方统计模型。结果:在1990年至2024年期间,VigiBase的38,758,077份报告中,230,371份涉及氯氮平。在ATC代码N05A的抗精神病药物中,检测到含有氯氮平的ddi包括氨硫pride、氯丙嗪、氟哌啶醇、鲁拉西酮、奥氮平、戊氟醇、利培酮、舒必利、佐替平和zuclopenthol。在Ω收缩测量模型(β = 0.295, 95%置信区间:0.119-0.471,p = 0.002)中观察到多巴胺D4受体占用率与信号值的点估计之间存在显著关联,并在所有频率统计模型中得到重复。结论:这些发现提示多巴胺D4受体占据在癫痫发作中与其他抗精神病药物增加氯氮平相关的潜在作用。需要进一步的大规模流行病学研究来验证这些发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.90
自引率
2.40%
发文量
35
审稿时长
10 weeks
期刊介绍: Therapeutic Advances in Psychopharmacology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of psychopharmacology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in psychopharmacology, providing a forum in print and online for publishing the highest quality articles in this area.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书